RCSB PDB - 8S53: X-ray crystal structure of CYP142 from Mycobacterium tuberculosis in complex with a fragment bound in two poses

 8S53

X-ray crystal structure of CYP142 from Mycobacterium tuberculosis in complex with a fragment bound in two poses


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.60 Å
  • R-Value Free: 0.175 
  • R-Value Work: 0.156 
  • R-Value Observed: 0.157 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 

Created with Raphaël 2.3.0Worse 01 BetterLigand structure goodness of fit to experimental dataBest fitted 3QOClick on this verticalbar to view details

This is version 1.0 of the entry. See complete history


Literature

Fragment-based development of small molecule inhibitors targeting Mycobacterium tuberculosis cholesterol metabolism.

Kavanagh, M.E.McLean, K.J.Gilbert, S.H.Amadi, C.Snee, M.Tunnicliffe, R.B.Arora, K.Boshoff, H.I.Fanourakis, A.Rebello-Lopez, M.J.Ortega-Muro, F.Levy, C.W.Munro, A.W.Leys, D.Abell, C.Coyne, A.G.

(2024) bioRxiv 

  • DOI: https://doi.org/10.1101/2024.10.28.620643
  • Primary Citation of Related Structures:  
    8S4M, 8S53

  • PubMed Abstract: 

    Mycobacterium tuberculosis ( Mtb ) is the world's most deadly infectious pathogen and new drugs are urgently required to combat the emergence of multi- (MDR) and extensively- (XDR) drug resistant strains. The bacterium specifically upregulates sterol uptake pathways in infected macrophages and the metabolism of host-derived cholesterol is essential for Mtb's long-term survival in vivo. Here, we report the development of antitubercular small molecules that inhibit the Mtb cholesterol oxidases CYP125 and CYP142, which catalyze the initial step of cholesterol metabolism. An efficient biophysical fragment screen was used to characterize the structure-activity relationships of CYP125 and CYP142, and identify a non-azole small molecule 1a that can bind to the heme cofactor of both enzymes. A structure-guided fragment-linking strategy was used to optimize the binding affinity of 1a , yielding a potent dual CYP125/142 inhibitor 5m (K D CYP125/CYP142 = 0.04/0.16 μM). Compound 5m potently inhibits the catalytic activity of CYP125 and CYP142 in vitro (K I values < 0.1 μM), and rapidly depletes Mtb intracellular ATP (IC 50 = 0.15 μM). The compound has antimicrobial activity against both drug susceptible and MDR Mtb ( MIC 99 values 0.4 - 1.5 μM ) in extracellular assays, and inhibits the growth of Mtb in human macrophages (MIC = 1.7 μM) with good selectivity over mammalian cytotoxicity (LD 50 ≥ 50 μM). The combination of small molecule inhibitors and structural data reported here provide useful tools to study the role of cholesterol metabolism in Mtb and are a promising step towards novel antibiotics targeting bioenergetic pathways, which could be used to help combat MDR-TB.


  • Organizational Affiliation

    Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Steroid C26-monooxygenase418Mycobacterium tuberculosis H37RvMutation(s): 0 
Gene Names: cyp142cyp142A1Rv3518cMTV023.25c
EC: 1.14.15.28
UniProt
Find proteins for P9WPL5 (Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv))
Explore P9WPL5 
Go to UniProtKB:  P9WPL5
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP9WPL5
Sequence Annotations
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.60 Å
  • R-Value Free: 0.175 
  • R-Value Work: 0.156 
  • R-Value Observed: 0.157 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 55.458α = 90
b = 65.772β = 90
c = 130.655γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
DIALSdata reduction
Aimlessdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 

Created with Raphaël 2.3.0Worse 01 BetterLigand structure goodness of fit to experimental dataBest fitted 3QOClick on this verticalbar to view details

Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Biotechnology and Biological Sciences Research Council (BBSRC)United Kingdom--

Revision History  (Full details and data files)

  • Version 1.0: 2025-01-29
    Type: Initial release